New York, June 1, 2026, 10:06 EDT
- Pulmatrix shares were quoted at $1.37 shortly after the open, down 1.44%, on thin volume.
- No fresh company catalyst was listed Monday; the latest major update remained the May 15 quarterly report and Eos merger update.
- Current Pulmatrix holders are expected to own about 6% of the combined company if the Eos deal closes.
Pulmatrix Inc shares slipped in thin early Nasdaq trading on Monday, with the stock again moving around the planned merger with Eos SENOLYTIX rather than a fresh drug-data catalyst.
The stock was quoted at $1.37, down 1.44%, at 09:30:01 a.m. ET, with volume of about 1,010 shares against a three-month average of roughly 50,490. Investing.com listed the company’s market value at about $5 million and its 52-week range at $1.16 to $9.23. The Nasdaq Composite was down 0.15% in the same market snapshot, while the S&P 500 was off 0.09%.
That matters now because Pulmatrix is trading less like a standard clinical-stage biotech and more like a small public shell tied to a pending transaction. The company’s May filing said Eos holders and financing participants are expected to own about 94% of the combined company after closing, while Pulmatrix holders are expected to own about 6% on a fully diluted basis.
There was no new company release in Pulmatrix’s investor feed on Monday. The latest listed release remained the May 15 first-quarter update, and the company’s filings page showed the May 15 10-Q as the most recent quarterly report.
Pulmatrix and Eos signed their merger agreement on March 26. The 10-Q said closing is subject to stockholder approvals, effectiveness of a registration statement filed with the U.S. Securities and Exchange Commission, and Nasdaq approval for listing shares to be issued in the deal.
The deal is a reverse-merger style pivot, meaning the private company’s business would become the operating business inside the public company if the transaction closes. Pulmatrix has said Eos, a Houston-based biotech developing gerotherapeutic peptides aimed at mitochondrial dysfunction in aging-related disease, would continue as the business of the combined company.
Peter Ludlum, Pulmatrix’s interim chief executive officer, said in the May update that the first-quarter focus was on securing a “strategic transaction.” He also said common stockholders would receive “approximately 6% interest” in the new combined company, separate from the preferred-stock investment tied to the deal.
The balance sheet explains the pressure. Pulmatrix reported $3.3 million in cash and cash equivalents at March 31, plus $0.7 million in restricted cash. Management said there was “substantial doubt” about the company’s ability to continue as a going concern — an accounting warning about whether a company can keep operating for the next year — without the Eos merger closing.
Pulmatrix has also stopped spending meaningfully on its own pipeline. Research and development expense was less than $100,000 in the first quarter, and the company said all clinical development is on hold while it seeks to license or monetize clinical assets.
Competitive context is narrow. Pulmatrix is not fighting a same-day clinical readout against larger inhaled-drug players; it is trying to preserve value from its iSPERSE dry-powder delivery platform. The company said iSPERSE is licensed to MannKind and Cipla Technologies in certain fields, while its own PUR3100 migraine program and PUR1800 respiratory program remain dependent on funding, partners or monetization.
But the trade could break either way. If the Eos transaction closes, Pulmatrix holders get a small stake in a new biotech story; if it fails, the 10-Q says the company may seek other strategic alternatives or pursue dissolution and liquidation, and any new funding could come on terms that further dilute common shareholders.
The next watch items are procedural, not dramatic: a registration-statement update, stockholder-vote timing, Nasdaq listing approval for the merger shares, and any notice on monetizing the old Pulmatrix assets. Until then, the stock may keep moving on sparse volume, where small orders can make the tape look louder than the news.
